Cargando…
The Risk of Muscular Events Among New Users of Hydrophilic and Lipophilic Statins: an Observational Cohort Study
BACKGROUND: Statins are effective lipid-lowering drugs for the prevention of cardiovascular disease, but muscular adverse events can limit their use. Hydrophilic statins (pravastatin, rosuvastatin) may cause less muscular events than lipophilic statins (e.g. simvastatin, atorvastatin) due to lower p...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8390626/ https://www.ncbi.nlm.nih.gov/pubmed/33751411 http://dx.doi.org/10.1007/s11606-021-06651-6 |
_version_ | 1783743116742754304 |
---|---|
author | Mueller, Alexandra M. Liakoni, Evangelia Schneider, Cornelia Burkard, Theresa Jick, Susan S. Krähenbühl, Stephan Meier, Christoph R. Spoendlin, Julia |
author_facet | Mueller, Alexandra M. Liakoni, Evangelia Schneider, Cornelia Burkard, Theresa Jick, Susan S. Krähenbühl, Stephan Meier, Christoph R. Spoendlin, Julia |
author_sort | Mueller, Alexandra M. |
collection | PubMed |
description | BACKGROUND: Statins are effective lipid-lowering drugs for the prevention of cardiovascular disease, but muscular adverse events can limit their use. Hydrophilic statins (pravastatin, rosuvastatin) may cause less muscular events than lipophilic statins (e.g. simvastatin, atorvastatin) due to lower passive diffusion into muscle cells. OBJECTIVE: To compare the risk of muscular events between statins at comparable lipid-lowering doses and to evaluate if hydrophilic statins are associated with a lower muscular risk than lipophilic statins. DESIGN/SETTING: Propensity score-matched cohort study using data from the United Kingdom-based Clinical Practice Research Datalink (CPRD) GOLD. PATIENTS: New statin users. Cohort 1: pravastatin 20-40 mg (hydrophilic) vs simvastatin 10-20 mg (lipophilic), cohort 2: rosuvastatin 5-40 mg (hydrophilic) vs atorvastatin 10-80 mg (lipophilic), and cohort 3: simvastatin 40-80 mg vs atorvastatin 10-20 mg. MAIN MEASURES: The outcome was a first record of a muscular event (myopathy, myalgia, myositis, rhabdomyolysis) during a maximum follow-up of 1 year. KEY RESULTS: The propensity score-matched cohorts consisted of 1) 9,703, 2) 7,032, and 3) 37,743 pairs of statin users. Comparing the risk of muscular events between low-intensity pravastatin vs low-intensity simvastatin yielded a HR of 0.86 (95% CI 0.64-1.16). In the comparison of moderate- to high-intensity rosuvastatin vs equivalent doses of atorvastatin, we observed a HR of 1.17 (95% CI 0.88-1.56). Moderate- to high-intensity simvastatin was associated with a HR of 1.33 (95% CI 1.16-1.53), when compared with atorvastatin at equivalent doses. LIMITATIONS: We could not conduct other pairwise comparisons of statins due to small sample size. In the absence of a uniform definition on the comparability of statin doses, the applied dose ratios may not fully match with all literature sources. CONCLUSIONS: Our results do not suggest a systematically lower risk of muscular events for hydrophilic statins when compared to lipophilic statins at comparable lipid-lowering doses. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11606-021-06651-6. |
format | Online Article Text |
id | pubmed-8390626 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-83906262021-09-14 The Risk of Muscular Events Among New Users of Hydrophilic and Lipophilic Statins: an Observational Cohort Study Mueller, Alexandra M. Liakoni, Evangelia Schneider, Cornelia Burkard, Theresa Jick, Susan S. Krähenbühl, Stephan Meier, Christoph R. Spoendlin, Julia J Gen Intern Med Original Research BACKGROUND: Statins are effective lipid-lowering drugs for the prevention of cardiovascular disease, but muscular adverse events can limit their use. Hydrophilic statins (pravastatin, rosuvastatin) may cause less muscular events than lipophilic statins (e.g. simvastatin, atorvastatin) due to lower passive diffusion into muscle cells. OBJECTIVE: To compare the risk of muscular events between statins at comparable lipid-lowering doses and to evaluate if hydrophilic statins are associated with a lower muscular risk than lipophilic statins. DESIGN/SETTING: Propensity score-matched cohort study using data from the United Kingdom-based Clinical Practice Research Datalink (CPRD) GOLD. PATIENTS: New statin users. Cohort 1: pravastatin 20-40 mg (hydrophilic) vs simvastatin 10-20 mg (lipophilic), cohort 2: rosuvastatin 5-40 mg (hydrophilic) vs atorvastatin 10-80 mg (lipophilic), and cohort 3: simvastatin 40-80 mg vs atorvastatin 10-20 mg. MAIN MEASURES: The outcome was a first record of a muscular event (myopathy, myalgia, myositis, rhabdomyolysis) during a maximum follow-up of 1 year. KEY RESULTS: The propensity score-matched cohorts consisted of 1) 9,703, 2) 7,032, and 3) 37,743 pairs of statin users. Comparing the risk of muscular events between low-intensity pravastatin vs low-intensity simvastatin yielded a HR of 0.86 (95% CI 0.64-1.16). In the comparison of moderate- to high-intensity rosuvastatin vs equivalent doses of atorvastatin, we observed a HR of 1.17 (95% CI 0.88-1.56). Moderate- to high-intensity simvastatin was associated with a HR of 1.33 (95% CI 1.16-1.53), when compared with atorvastatin at equivalent doses. LIMITATIONS: We could not conduct other pairwise comparisons of statins due to small sample size. In the absence of a uniform definition on the comparability of statin doses, the applied dose ratios may not fully match with all literature sources. CONCLUSIONS: Our results do not suggest a systematically lower risk of muscular events for hydrophilic statins when compared to lipophilic statins at comparable lipid-lowering doses. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11606-021-06651-6. Springer International Publishing 2021-03-09 2021-09 /pmc/articles/PMC8390626/ /pubmed/33751411 http://dx.doi.org/10.1007/s11606-021-06651-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Research Mueller, Alexandra M. Liakoni, Evangelia Schneider, Cornelia Burkard, Theresa Jick, Susan S. Krähenbühl, Stephan Meier, Christoph R. Spoendlin, Julia The Risk of Muscular Events Among New Users of Hydrophilic and Lipophilic Statins: an Observational Cohort Study |
title | The Risk of Muscular Events Among New Users of Hydrophilic and Lipophilic Statins: an Observational Cohort Study |
title_full | The Risk of Muscular Events Among New Users of Hydrophilic and Lipophilic Statins: an Observational Cohort Study |
title_fullStr | The Risk of Muscular Events Among New Users of Hydrophilic and Lipophilic Statins: an Observational Cohort Study |
title_full_unstemmed | The Risk of Muscular Events Among New Users of Hydrophilic and Lipophilic Statins: an Observational Cohort Study |
title_short | The Risk of Muscular Events Among New Users of Hydrophilic and Lipophilic Statins: an Observational Cohort Study |
title_sort | risk of muscular events among new users of hydrophilic and lipophilic statins: an observational cohort study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8390626/ https://www.ncbi.nlm.nih.gov/pubmed/33751411 http://dx.doi.org/10.1007/s11606-021-06651-6 |
work_keys_str_mv | AT muelleralexandram theriskofmusculareventsamongnewusersofhydrophilicandlipophilicstatinsanobservationalcohortstudy AT liakonievangelia theriskofmusculareventsamongnewusersofhydrophilicandlipophilicstatinsanobservationalcohortstudy AT schneidercornelia theriskofmusculareventsamongnewusersofhydrophilicandlipophilicstatinsanobservationalcohortstudy AT burkardtheresa theriskofmusculareventsamongnewusersofhydrophilicandlipophilicstatinsanobservationalcohortstudy AT jicksusans theriskofmusculareventsamongnewusersofhydrophilicandlipophilicstatinsanobservationalcohortstudy AT krahenbuhlstephan theriskofmusculareventsamongnewusersofhydrophilicandlipophilicstatinsanobservationalcohortstudy AT meierchristophr theriskofmusculareventsamongnewusersofhydrophilicandlipophilicstatinsanobservationalcohortstudy AT spoendlinjulia theriskofmusculareventsamongnewusersofhydrophilicandlipophilicstatinsanobservationalcohortstudy AT muelleralexandram riskofmusculareventsamongnewusersofhydrophilicandlipophilicstatinsanobservationalcohortstudy AT liakonievangelia riskofmusculareventsamongnewusersofhydrophilicandlipophilicstatinsanobservationalcohortstudy AT schneidercornelia riskofmusculareventsamongnewusersofhydrophilicandlipophilicstatinsanobservationalcohortstudy AT burkardtheresa riskofmusculareventsamongnewusersofhydrophilicandlipophilicstatinsanobservationalcohortstudy AT jicksusans riskofmusculareventsamongnewusersofhydrophilicandlipophilicstatinsanobservationalcohortstudy AT krahenbuhlstephan riskofmusculareventsamongnewusersofhydrophilicandlipophilicstatinsanobservationalcohortstudy AT meierchristophr riskofmusculareventsamongnewusersofhydrophilicandlipophilicstatinsanobservationalcohortstudy AT spoendlinjulia riskofmusculareventsamongnewusersofhydrophilicandlipophilicstatinsanobservationalcohortstudy |